Tessella » life-sciences

Tessella expertise helps BiOxyDyn meet critical milestone in commercialisation of Oxygen Enhanced MRI technology

fowj — Tue, 26 Jul 2011 09:30:53 +0000

When BiOxyDyn, (www.bioxydyn.com), a spin out company from Manchester University, needed to turn their innovative research and Intellectual Property (IP) in non-invasive medical imaging into a commercially robust, well-architected and fully-documented set of software tools, they called on Tessella’s unique blend of expertise in image analysis and scientific software engineering. The collaboration has enabled BiOxyDyn to meet the first critical milestone in the commercialisation of their technology – allowing them to more fully engage with potential partners and customers, capitalise on their market lead, attract additional investment and better meet regulatory requirements.

Read the full article (PDF)

GDDIS Summit 2011; November 7th to 8th, Orlando, Florida, US

teac — Fri, 08 Jul 2011 16:20:36 +0000

Tessella are proud sponsors of the GDDIS Summit 2011 taking place on November 7th – 8th at the prestigious Waldorf Astoria in Orlando, Florida, US.

Meet Dr Andrew Chadwick, Principal Consultant for Life Sciences at Tessella and Grant Stephen, CEO of Tessella Inc at stand number 12.

If you would like a prearranged meeting please email info@tessella.com and we will be happy to accommodate you.

To learn more about this event or to register as a delegate, visit www.gddis.com

Pharmaceutical industry moving to smarter clinical trials

fowj — Wed, 25 May 2011 16:54:24 +0000

Focus group and survey confirm growing complexity of drug development and increasing adoption of smarter clinical trials

Tom Parke, Head of Clinical Technologies, Tessella

I was lucky enough to join a focus group at the recent 8th Annual SAS Health Care & Life Sciences Executive Conference (http://www.sas.com/news/preleases/hlsconf-clinicaltrials.html). The group comprising of selected pharmaceutical industry executives, SAS, Berry Consultants and Tessella discussed clinical research best practices.

So what did the group observe? Two points struck me:

1. The growth of personalised medicines, increased use of biomarkers and intensification of comparative effectiveness studies are making drug development more complex than ever. Smarter clinical trials are seen as a key method to respond to this complexity.
2. Concern that companies will need to break down silos and increase inter-operability between groups and IT systems in order to execute trials in an agile and flexible fashion.

The second point could be seen as pessimistic, yet the recent Perceptive Informatics global survey (http://www.perceptive.com/news/press-releases/2011/perceptive-informatics-global-survey-results-show-growing-indust/) is encouraging. It shows that despite these concerns the industry’s willingness to use innovative approaches in clinical trials, such as adaptive trials, is growing. During a recent webinar presented by Perceptive and Tessella, more than 300 industry professionals answered questions about implementing adaptive trials. The survey showed that 80% of respondents were considering implementing adaptive trials within the next year.

Drug Discovery and Development: Overcoming Bias

teac — Thu, 24 Mar 2011 09:46:33 +0000

Matthew Segall, Optibrium Ltd., Cambridge, U.K. and
Andrew Chadwick, Tessella plc, Burton upon Trent, U.K.

When human biases distort drug discovery decision-making, software tools can guide thinking towards objective answers…read more

European Pharmaceutical Review: New Paper from Optibrium and Tessella

teac — Tue, 23 Nov 2010 09:26:04 +0000

Optibrium, a provider of software solutions for drug discovery, and Tessella, the information technology and consulting services company and world leaders in digital preservation technology, published a new paper highlighting that scientists’ instincts may not always lead them to making good drug discovery decisions. The challenges of decision-making arise from the importance of multiple/conflicting criteria to the success of a potential drug molecule, the large amount of data generated and the inherent uncertainty in that data…read more

Perceptive User Group Meeting; October 26-28, 2010, Philadelphia, PA

teac — Mon, 18 Oct 2010 09:31:15 +0000

Tessella’s Head of Clinical Trials Solutions Tom Parke, will be speaking at the Perceptive User Group Meeting taking place on October 26-28, 2010 in Philadelphia, PA.

Tom Parke be giving a talk on:

What adaptive clinical trials promise

What it takes to run an adaptive trial

What can go wrong and how to prevent it, dodge it or cope with it.

To find out more about this event or to register online, visit www.perceptive.com/news/2010-user-group-meeting/

Webinar; Optimising through the Discovery to Clinical transition

teac — Sun, 19 Sep 2010 14:09:14 +0000

As pharma R&D leaders bring together their discovery and early development organizations they face tough decisions. How do you optimize project planning across a seamless R&D process? What is the right balance between risk, cost and value in the face of uncertainty? When and how should you deploy predictive technologies such as biomarkers? This webinar will show how the combination of deep business and scientific experience can help you analyze these hard decisions, find the most effective plans for your projects and determine the best approach to biomarkers and screening for specific therapeutic areas.

Join Dr Andrew Chadwick, Principal Consultant at Tessella, as he discusses with Prof Orest Hurko, Senior Clinical Consultant, Biologics Consulting Group, Inc, how to get more value from decisions on predictive technology provision and planning.

Bio-IT World: FACTS 2 Makes Most Clinical Trials Eligible for Design Simulation

teac — Fri, 17 Sep 2010 07:47:44 +0000

By Deborah Borfitz

The first upgrade to a one-of-a-kind simulation tool co-developed by Tessella and Berry Consultants significantly enlarges the proportion of clinical studies that can benefit from simulation of the design…read more

Accelerating Development & Advancing Personalized Therapy (ADAPT 2010); September 13-16th, 2010, Hyatt Regency Crystal City, Arlington, VA

teac — Thu, 16 Sep 2010 12:51:27 +0000

Tessella are corporate sponsors of ADAPT 2010, taking place on September 13-16th, 2010 at the Hyatt Regency Crystal City, Arlington, VA, USA.

Tom Parke, head of clinical trial solutions at Tessella is a speaker at the event and will be giving a talk on Adpative Clinical Trials and Biomarkers and Scott Berry, President and Senior Statistical Scientist at Berry Consultants will be giving a talk on Designing Clinical Trials for Personalised Medicine at the event.

To find out more or to register online, visit www.adaptcongress.com

2010 Accelrys European User Group Meeting; October 26-28th, Barcelona, Spain

teac — Tue, 14 Sep 2010 10:13:21 +0000

Tessella are sponsoring this year’s 2010 Accelrys European User Group Meeting, taking place at the Dolce Sitges Hotel in Barcelona, Spain on October 26-28th 2010.

Mark Roberts from Tessella and Ed Ainscow from AstraZeneca will be speaking at the event. The title of their abstract is ‘A Flexible Platform for Processing High-Content Screening Data’ which will focus on how Pipeline Pilot has been used to implement a highly flexible platform for processing high-content data.

To find out more or to register online visit www.accelrys.com